N-(5,6,7,8-tetrahydropyrido(2,3-d)pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives
Abstract
A compound selected from the group consisting of a glutamic acid derivative of the formula: in which:<br /> R¹ is -OH or -NH₂;<br /> R² is hydrogen or a carboxy protecting group;<br /> R³ is a carbon-carbon bond, alkylene of 1 to 4 carbon atoms, cyclohexylene, or R⁴ is hydrogen or an amino protecting group;<br /> Q is -S- or -O-;<br /> R⁵ is hydrogen, chloro or fluoro; and<br /> the configuration about the carbon atom designated * is S; and<br /> the pharmaceutically acceptable salts thereof. Also disclosed is a method of combatting neoplastic growth in a mammal and a pharmaceutical composition for combatting neoplastic growth in a mammal making use of the above compound.

Term
Term ended
Projected expiry passed 4 May 2009, 17.4 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
2 sheets
Sheet 1 Sheet 2
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| WO8605181A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report |
38 members in 22 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 198201 | United States of America | – | |
| 19820188 | United States of America | A | |
| 19820188 | United States of America | A | |
| 198207 | United States of America | – | |
| 19820788 | United States of America | A | |
| 19820788 | United States of America | A | |
| US19880198201 | – | – | – |
| US19880198207 | – | – | – |
Members38
| Document | Office | Kind | |
|---|---|---|---|
| DK215289D0 | Denmark | D0 | |
| US4882333A | United States of America | A | |
| US4882334A | United States of America | A | |
| IE891767L | Ireland | L | |
| DK215289A | Denmark | A | |
| EP0343801A2 | European Patent Office (EPO) | A2 | |
| AU3510989A | Australia | A | |
| PT90635A | Portugal | A | |
| IL90179A0 | Israel | A0 | |
| IL90179D0 | Israel | D0 | |
| CN1038098A | China | A | |
| HUT50342A | Hungary | A | |
| ZA893714B | South Africa | B | |
| JPH0267281A | Japan | A | |
| NZ229242A | New Zealand | A | |
| KR900018100A | Republic of Korea | A | |
| EP0343801A3This record | European Patent Office (EPO) | A3 | |
| AU611027B2 | Australia | B2 | |
| HU205356B | Hungary | B | |
| PH26650A | Philippines | A | |
| RU2002747C1 | Russian Federation | C1 | |
| IL90179A | Israel | A | |
| CN1025334C | China | C | |
| EP0343801B1 | European Patent Office (EPO) | B1 | |
| AT109480T | Austria | T | |
| ATE109480T1 | Austria | T1 | |
| DE68917211D1 | Germany | D1 | |
| ES2057116T3 | Spain | T3 | |
| PT90635B | Portugal | B | |
| DE68917211T2 | Germany | T2 | |
| IE63620B1 | Ireland | B1 | |
| HK1000284A1 | Hong Kong, China | A1 | |
| KR0131589B1 | Republic of Korea | B1 | |
| CY2055B1 | Cyprus | B1 | |
| JP2818198B2 | Japan | B2 | |
| DK172753B1 | Denmark | B1 | |
| CA1340631C | Canada | C | |
| BR1101026A | Brazil | A |
50 legal events, as 6 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Notification of lapseLapsedST | ST | FR | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| Validation in greece3013836FG4A | FG4A | GR | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Fr: translation filedET | ET | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0343801
- Publication, DOCDB
- 0343801
- Publication, EPODOC
- EP0343801
- Application
- 304499
- Application, DOCDB
- 89304499
- Application, EPODOC
- EP19890304499
Titles3
- German
- N-(5,6,7,8-Tetrahydropyrido(2,3-d)pyrimidin-6-yl-alkanoyl)-glutaminsäure-Derivate
- English
- N-(5,6,7,8-tetrahydropyrido(2,3-D)pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives
- French
- Dérivés de l'acide N-(5,6,7,8-tétrahydropyrido(2,3-d)pyrimidin-6-yl-alkanoyl)-glutamique
Classification
- CPC, 3
- C07D471/04
- Y02P20/55
- A61P35/00
- IPC, 4
- A61K31 505
- A61K31 519
- A61P35 00
- C07D471 04
Designated states1
- Contracting states, 1
- Sweden